Trial Profile
A Phase 2a/2b study of BMS-650032 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects with Genotypes 1 and 4 Chronic Hepatitis C Infection. Revised Protocol 06, incorporating Protocol Amendments 03, 05, 06, 07, 08 and 10 + Amendment Number 09 Site-Specific - Ireland (1.0, dated 27-Oct-11)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs Asunaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 01 Jun 2018 Results (n=1239) of pooled analysis (NCT01012895, NCT01030432, NCT01051414, NCT01497834 and NCT01581203) published in the Infectious Diseases and Therapy
- 28 Apr 2013 Results reporting sustained virological response rates at 12 and 24 weeks post-treatment were presented at the 48th Annual Meeting of the European Association for the Study of the Liver.
- 27 Apr 2013 Primary endpoint 'Sustained-virological-response-rate' has been met.